Cancer immunotherapy has fundamentally changed the landscape of oncology in recent years and significant resources are invested into immunotherapy research. It is in the interests of researchers and clinicians to identify promising and less promising trends in this field in order to rationally allocate resources. This requires a quantitative large-scale analysis of cancer immunotherapy related databases.
Introduction
Cancer immunotherapy is widely regarded as one of the most promising approaches for treating metastatic cancer. 1 It has been in the focus of basic, translational and clinical research for years and significant resources have been invested in finding new immunotherapy treatments with clinical efficacy.
Anecdotally, most clinicians and researchers in the field are aware that clinical translation has not been equally successful for each subfield over the last years. For example, it is well-known that therapeutic vaccines were intensely investigated and shaped immunotherapy for years but have not yet made a direct clinical impact. Also, immunotherapy quickly reached clinical application in melanoma, 2 while gastrointestinal cancer types are still lagging behind. 3 These shifts within the cancer immunotherapy field are highly relevant for clinicians, researchers and funding agencies. However, until now, these changes have not been quantified in a way that allows an unbiased assessment of past and possible future trends.
In the present study, we quantified the development of the cancer immunotherapy field from 1986 to 2017 to reveal previously hidden trends. This type of quantitative and unbiased analysis is of high interest to researchers and clinicians because it can guide the allocation of resources for future research and clinical trials. Specifically, we focused on the comparison of treatment approaches, translational research topics and different tumor entities (organ of the primary tumor, according to the International Statistical Classification of Diseases and Related Health Problems, ICD-10). Among various types of cancer immunotherapy, 4 we looked at the development of oncolytic viruses, 5 cell-based therapies, 6 therapeutic vaccines, 7 checkpoint inhibitors 8, 9 as well as chemotherapy and radiation therapy. These treatment types were separately analyzed for all tumor entities in order find out which approaches would be most promising in specific entities in the future. To quantify developments in basic and translational cancer research, we included a wide range of topics such as the combination of immunotherapy with stroma 10 and cancer-associated fibroblasts, 11 angiogenesis, 12 tumor-specific antigens, 13 neoantigens, 14 20, 21 as well as metabolism. 22 All trends were analyzed over time, keeping in mind that the field was profoundly changed by landmark events such as the first clinical report of effective checkpoint inhibition in cancer patients in 2003. 23, 24 Inhibitors of immune receptors and ligands are currently the largest class of approved immunotherapy drugs. 25, 26 To investigate this subfield in detail, we used a graph-based approach to visualize which of these checkpoint pathways was in the focus of research efforts during the last years. Also, this analysis was used to identify promising combination approaches to target checkpoint signaling pathways.
In short, we present a novel method for data collection, analysis and visualization of changing trends in cancer immunotherapy from 1986 to 2017 and discuss their implications.
Methods

Database queries
Based on previous literature reviews and other publicly available resources, we manually curated a list of keywords to enable the comparison of different tumor entities (organ of the primary tumor, e.g. brain, breast, sarcoma, etc., complete list in Suppl. Table 1) , treatment approaches (e.g. adoptive cell transfer, oncolytic viruses, checkpoint inhibition, etc., complete list in Suppl. Table 2 ), translational research topics (e.g. apoptosis, stem cells, epigenetics, etc., complete list in Suppl. Table 3 ) and cell types (e.g. myeloid, lymphoid, etc., complete list in Suppl. 27 For clinical trials, the master keyword was: "cancer immunotherapy". For clinical trials, all accessible trial metadata (title, description and structured information) was downloaded from respective databases. All database queries were made in November 2017.
Data analysis
All data analyzes and visualizations were conducted with selfdeveloped MATLAB scripts (R2017a, MathWorks, Natick, MA, USA). Data were normalized to the number of total immunotherapy articles (or trials, respectively) in each year. Data points were smoothed with a moving average filter (lowpass filter with a coefficient equal to the reciprocal of the time span and a window size of five years). All scripts are released open-source and are available under the following DOI: 10.5281/zenodo.1190620
Trumpet plot
To illustrate the temporal variation of the incidence of keyword groups, we used the self-developed "trumpet plot". Normalized and smoothed timelines were visualized as the height of a "trumpet" shape in a 2D. In 3D, the diameter of a cylinder represented the normalized number of research items in a given year with time as the vertical axis. Perceptually optimized colour scales from the "Color Brewer" project were used to visualize data. 28 
Graph-based analysis and network plot
To investigate the degree of connectivity between similar keywords in a specific subfield, we used a graph-based analysis. This was employed for keywords that represented different immune checkpoint molecules e.g. PD-1, PD-L1, CTLA-4, CD80, etc. (full list in Suppl. Table 1 ). Each keyword was represented by a node which was visualized as a circle. The size and color of the circle depicted the number of research items matching this keyword. The distance between the node and the width of the connecting edge represented the co-occurrence of two keywords. Logarithmic scaling was used for the circle size and the edge width. Isolated nodes without any connection to other nodes were discarded. Low-abundant nodes (< 10 hits) and edges were also discarded.
Results
Shift from vaccination to checkpoint inhibition in clinical and translational studies
First, we analyzed the contribution of major treatment types to the cancer immunotherapy literature. In the PubMed database, chemotherapy was the most frequent treatment that articles could be matched to (33% in 2017, Fig. 1A ). Checkpoint inhibition grew significantly (indicated by a C in the graphs) from 2015 and was the second most abundant treatment type in 2017. Therapeutic vaccination as a form of cancer immunotherapy dropped from position 1 to position 3 in 2017, with significant decrease (indicated by a diamond in the graphs) between 2015 and 2017. These trends were even more pronounced in clinical trials where checkpoint inhibition was matched in more than 50% of all items in 2017, chemotherapy being second with 26% and vaccination steadily dropping to only 9% of clinical trials in 2017 ( Fig. 2A) . Adoptive cell-based therapies (including chimeric antigen receptor [CAR] T-cells) contributed to 15% of all research items in 2017 and to 7% of all clinical trials (Fig. 1A and Fig. 2A ).
Lung and gastrointestinal cancer as prime targets for immunotherapy
Next, we analyzed cancer immunotherapy research efforts for each tumor entity. In articles indexed in PubMed, hematological neoplasias (hema.) were the prime immunotherapy target until 2015/2016, but have decreased significantly since, yielding to skin and gastrointestinal (GI) neoplasms (Fig. 1B) . Among the top five tumor entities (skin, GI, hema., respiratory-thoracic [lung] and urinary tract), only lung and GI showed a significant growth in the last five years (Fig. 1B) . This pattern matched clinical trial data (Fig. 2B ) where lung and GI tumors were the top two cancer entities by far. Again, hematological neoplasms rapidly (and in one year significantly) decreased in importance; also, sarcoma continuously decreased in importance over the years (Fig. 2B) .
Subsequently, we asked how the different therapy approaches were reflected in each major tumor entity. In the research literature, checkpoint inhibitors have increased in importance in the last five years in all top five tumor entities (Fig. 1D) . The reverse trend can be observed in vaccination and chemotherapy, although these still have a large presence. Much more pronounced effects were observed in clinical trials (Fig. 2D) : Here, lung and GI neoplasms were the two most dynamically growing field with growth in skin cancer reaching a plateau and hematological neoplasms vanishing almost completely.
A transient 1990s interest in myeloid cells left no trace in the clinic
Cancer immunotherapy aims to (re)invigorate the host immune response against malignant cells and all types of cancer immunotherapy use cells in the tumor microenvironment as their effectors. We analyzed the quantitative contribution of cell types in the immunotherapy literature. Items related to myeloid cells significantly increased its presence in PubMed in the late 1990s (Fig. 1C) , matching a large contribution to clinical trials at that time (Fig. 2C) . However, this transient interest in myeloid cells plateaued in the scientific literature and rapidly decreased in clinical trials. Not surprisingly, lymphoid cells were the largest single group of cells in 2017 in scientific publications and clinical trials.
Revival of radiation and chemo-immunotherapy
Having analyzed major trends among treatment types, cancer types and cell types, we looked for non-obvious trends in the dataset. We found that among treatment types, radiation was only at position five in scientific articles (Fig. 1A) but at position three in clinical trials ( Fig. 2A) . In both cases, the growth rate in 2017 significantly exceeded that of previous years. These trends followed a decrease during the early 2000s in radiation therapy in articles and clinical trials (Fig. 1A and Fig. 2A ). Based on these data, we conclude that we are currently witnessing a revival of the use of radiation in cancer immunotherapy.
We hypothesized that other non-obvious trends might be hidden in treatment combinations and therefore analyzed cooccurrence of treatment types in clinical trials (Fig. 3A) . In this analysis, the diagonal of the matrix corresponds to Fig. 2A . We found that the only markedly increasing treatment combination is chemotherapy plus checkpoint inhibition (Fig. 3A) . In contrast, virtually no registered clinical trials investigate the combinations vaccination plus checkpoint inhibition or adoptive cellular therapy plus checkpoint inhibition.
Stroma and apoptosis in gastrointestinal cancer
Our automatic approach for database mining allowed for an analysis of translational research topics per tumor type. For clarity, only a part of this analysis is shown in Fig. 3B . We found that among translational research topics in immunotherapy articles, angiogenesis is decreasing in importance in all major cancer entities. In contrast, apoptosis (and other forms of cell death as well as autophagy) is rapidly gaining ground in GI, lung and skin cancer (Fig. 3B) . Interestingly, the quantitative contribution of cancer stroma to immunotherapy articles is stagnating or decreasing in all major cancer entities except GI cancer (Fig. 3B ). Complementing our above-described finding that GI cancer is one of the most dynamically growing research topics in immunotherapy, we conclude that especially apoptosis and stroma are promising subfields in this entity.
Translational activities vary considerably between tumor types
Our next step was to examine the following question: how were preclinical research efforts, measured by the number of indexed items on PubMed, translated into clinical trials? To give a specific answer for all therapy types and major cancer entities, we compared timelines for multiple keywords in PubMed and clinical trial databases. We analyzed the number of clinical trials in the last five years (2012-2016) and normalized these numbers to the respective number of PubMed research items in the preceding five years. Among all therapy types, immune checkpoint inhibition stood out in terms of translational efficiency with close to 0.2 clinical trials per research paper in the reference periods (Fig. 4A ). Looking at various tumor entities, the differences in translational efficiency were not as large (Fig. 4B) . Highest translational efficiency was visible in immunotherapy of gastrointestinal and respiratory neoplasms while a low translational efficiency was seen in hematological malignancies with just 0.02 clinical trials per article (Fig. 4B) .
Another way of comparing the translational efficiency of immunotherapy subfields is to look at the development of clinical phase 1/2/3 trials over time. We matched all cancer immunotherapy trials registered at clinicaltrials.gov and all PubMed articles (when applicable) to one or more clinical phases. In the timelines in Fig. 5A , a small and stable percentage of PubMed articles can be matched to any clinical trial phase over time. Within registered clinical trials (Fig. 5B) , phase 1 and 2 trials are slowly increasing with phase 3 trials decreasing at the same time. However, in general, no pronounced trends were visible in this analysis. This picture changed markedly when analyzing clinical trials for each major tumor entity (Fig. 5C ): Phase 1 and 2 trials were rapidly increasing in gastrointestinal and lung cancer in the last five to ten years, but not in other major tumor entities. These data match our above-mentioned finding that GI and lung cancer are the most translationally active fields as compared to skin cancer, hematological neoplasias and other major cancer types.
Immune-checkpoint networks
Based on above-described results we concluded that checkpoint inhibition makes the largest quantitative contribution to research papers and clinical trials in immunotherapy research and is also the most efficient subfield in terms of clinical translation. Therefore, we performed a more specific analysis and asked how the contribution and intertwining of immune checkpoint molecules and drugs developed over time. Based on our timeline analysis (Fig. 1A) we estimated that around 2011, the increase in checkpoint inhibition publications started. We therefore used the following time frames, 1986-2010 and 2011-2016, to compare cooccurrence of checkpoint molecules in PubMed articles. These comparisons are shown in Fig. 6 as network plots. In 1986 to 2010, CD80 had the highest prevalence (Fig. 6A ) and a cluster around CD80/CD86/CD28/CD40L/CD40 dominated the immune checkpoint landscape in PubMed articles. In 2011 to 2016, a marked change was evident and PD-1/PD-L1, which were previously in the periphery of the network, and CTLA-4, which remained in the center, made by far the largest contribution (Fig. 6B) . Interestingly, CD80 (B7-1) still occupied a central "hub" position, linking two distant parts of the network with each other.
Discussion
Tumor immunotherapy research is a dynamically evolving field and has undergone profound changes in the last three decades.
While these developments might be implicitly known by researchers who have been deeply involved in the field for a long time, they are probably not apparent to most clinicians and scientists who are now confronted with immunotherapy. Moreover, researchers and clinicians working in the field may have cognitive biases and therefore may not be aware of well and poorly performing subfields of immunotherapy research. In this paper, we presented a quantitative, objective and comprehensive analysis of the changes in tumor immunotherapy research over time which can serve as a rational basis for further discussions.
Skin cancer (mainly melanoma) was the first tumor entity to have effective immunotherapy agents approved and is still in the focus of research papers. Yet, clinical trials now focus on gastrointestinal and respiratory cancers, two major disease classes associated with significant morbidity and mortality. Translational research means that new knowledge should be effectively transferred to the clinic. 29 Researchers pursuing translational research will therefore meet this aim more easily in an area where translation has been shown to be feasible. By extrapolating these current trends, translational research efforts would be most fruitful in gastrointestinal and respiratory cancer.
As a word of caution, we should also acknowledge that many unexpected breakthroughs come from previously unnoticed areas in biomedical research. Also, not all ongoing research efforts might be reflected by PubMed publications or registered clinical trials. Yet, for the tedious process of using research results from the laboratory to improve treatments in the clinic, a structured and objective projection of future trends can be very useful. Our data-driven analytics approach provides a starting basis for such endeavors. 
